Rayaldee Approved by FDA for Secondary HyperparathyroidismRayaldee Approved by FDA for Secondary Hyperparathyroidism

The FDA has approved calcifediol (Rayaldee, Opko Health, Inc) for the treatment of adults with secondary hyperparathyroidism associated with vitamin D insufficiency in stage 3 to 4 CKD. FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Alert Source Type: news